U.S. Biotech Company, Moderna, has continues to reap the rewards of its COVID-19 vaccine.
In the final quarter of 2021, the company had achieved net profits of $4.9 billion, it announced on Thursday.
In the last fiscal year, Moderna made a surplus of $12.2 billion, although the high research and development costs of the previous year had led to losses of $747 million.
However, all in all, the high demand for its vaccine led to revenues of $18.5 billion for 2021, up from $803 million the previous year.
Moderna’ signed advance purchase agreements for 2022 are valued at $19 billion, up from a predicted $18.5 billion in January.
The company holds additional signed options of approximately $3 billion.
READ ALSO: 3.5GHz Spectrum: MTN, Mafab pay $273.6m for licences
In comparison, rival company Pfizer expects revenues for its COVID vaccine of $32 billion for 2022.
The U.S-based pharmaceutical company developed its vaccine together with its German partner Biotech.
Major General Abubakar Rabe (rtd), who was abducted alongside his wife by bandits along the…
Suspected Boko Haram/ISWAP terrorists have reportedly torched a primary and secondary school in Kautikari village,…
Katsina State Governor Dikko Umar Radda has renewed his appeal to bandits operating in the…
President Bola Tinubu has expressed sadness over the death of retired Major-General Rabe Abubakar while…
Nigerian author Chimamanda Ngozi Adichie has accused Euracare Hospital of obstructing efforts to uncover the…
The Defence Headquarters (DHQ) has confirmed the death of retired Major General Rabe Abubakar, who…
This website uses cookies.